A T45 Labs Portfolio Company
VahatiCor provides an option for “no-option” refraction angina patients by relieving pain and discomfort with A-Fluxᵀᴹ Reducer.
A-Fluxᵀᴹ Reducer, a minimally-invasive and self-expanding device, is designed to restore natural blood flow and ease pressure, heaviness, and tightness of the chest.
A T45 Labs Portfolio Company
VahatiCor provides an option for “no-option” refraction angina patients by relieving pain and discomfort with A-Fluxᵀᴹ Reducer.
A-Fluxᵀᴹ Reducer, a minimally-invasive and self-expanding device, is designed to restore natural blood flow and ease pressure, heaviness, and tightness of the chest.
About the company
VahatiCor aims to alleviate angina burden for patients who have exhausted current medical therapies and wish to improve their heart micro-perfusion through implantable flow reduction devices.
Info@vahaticor.com
info@vahaticor.com
VahatiCor’s A-Fluxᵀᴹ Reducer is an investigational medical device that has not yet been approved by the FDA for commercial distribution in the United States. Any descriptions or claims about the device are based on investigational studies and clinical trials.